JP6948080B2 - 手術後の肝細胞癌患者を治療するための薬剤の製造における硫酸化オリゴ糖の使用 - Google Patents

手術後の肝細胞癌患者を治療するための薬剤の製造における硫酸化オリゴ糖の使用 Download PDF

Info

Publication number
JP6948080B2
JP6948080B2 JP2019547371A JP2019547371A JP6948080B2 JP 6948080 B2 JP6948080 B2 JP 6948080B2 JP 2019547371 A JP2019547371 A JP 2019547371A JP 2019547371 A JP2019547371 A JP 2019547371A JP 6948080 B2 JP6948080 B2 JP 6948080B2
Authority
JP
Japan
Prior art keywords
hepatocellular carcinoma
patients
invasive
tumor
microvascularly
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019547371A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020509035A (ja
JP2020509035A5 (cg-RX-API-DMAC7.html
Inventor
スタンリー チャン
スタンリー チャン
クアン−ラン ライ
クアン−ラン ライ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medigen Biotechnology Corp
Original Assignee
Medigen Biotechnology Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medigen Biotechnology Corp filed Critical Medigen Biotechnology Corp
Publication of JP2020509035A publication Critical patent/JP2020509035A/ja
Publication of JP2020509035A5 publication Critical patent/JP2020509035A5/ja
Application granted granted Critical
Publication of JP6948080B2 publication Critical patent/JP6948080B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2019547371A 2017-03-01 2018-02-24 手術後の肝細胞癌患者を治療するための薬剤の製造における硫酸化オリゴ糖の使用 Active JP6948080B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201762465170P 2017-03-01 2017-03-01
US62/465,170 2017-03-01
US201762504552P 2017-05-11 2017-05-11
US62/504,552 2017-05-11
US201762551770P 2017-08-29 2017-08-29
US62/551,770 2017-08-29
PCT/CN2018/077105 WO2018157762A1 (en) 2017-03-01 2018-02-24 Use of sulfated oligosaccharides in the manufacture of a medicament for treating patients with hepatocellular carcinoma after surgical resection

Publications (3)

Publication Number Publication Date
JP2020509035A JP2020509035A (ja) 2020-03-26
JP2020509035A5 JP2020509035A5 (cg-RX-API-DMAC7.html) 2020-07-09
JP6948080B2 true JP6948080B2 (ja) 2021-10-13

Family

ID=63357147

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019547371A Active JP6948080B2 (ja) 2017-03-01 2018-02-24 手術後の肝細胞癌患者を治療するための薬剤の製造における硫酸化オリゴ糖の使用

Country Status (6)

Country Link
US (1) US10842804B2 (cg-RX-API-DMAC7.html)
JP (1) JP6948080B2 (cg-RX-API-DMAC7.html)
KR (1) KR102265159B1 (cg-RX-API-DMAC7.html)
CN (1) CN110381953A (cg-RX-API-DMAC7.html)
TW (1) TWI693071B (cg-RX-API-DMAC7.html)
WO (1) WO2018157762A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113160911A (zh) * 2021-02-26 2021-07-23 杭州臻合健康科技有限公司 一种用于术前肝功能耐受性分析的评估系统
CN117476246B (zh) * 2023-12-25 2024-04-19 福建大数据一级开发有限公司 基于多类型复发事件的患者生存分析方法、介质及装置

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101156273B1 (ko) * 2004-03-04 2012-06-13 프로젠 파마슈티칼즈 리미티드 황산화 올리고사카라이드 유도체
JP2014516058A (ja) 2011-06-09 2014-07-07 基亜生物科技股▲ふん▼有限公司 肝癌の再発、悪化または転移の抑制に用いる医薬組成物

Also Published As

Publication number Publication date
US20180250317A1 (en) 2018-09-06
US10842804B2 (en) 2020-11-24
JP2020509035A (ja) 2020-03-26
TWI693071B (zh) 2020-05-11
KR102265159B1 (ko) 2021-06-17
CN110381953A (zh) 2019-10-25
WO2018157762A1 (en) 2018-09-07
TW201840324A (zh) 2018-11-16
KR20190120339A (ko) 2019-10-23

Similar Documents

Publication Publication Date Title
Tarantino et al. Interstitial lung disease induced by anti-ERBB2 antibody-drug conjugates: a review
Friedman et al. Phase II study of atezolizumab in combination with bevacizumab in patients with advanced cervical cancer
Lu et al. Perioperative toripalimab plus chemotherapy for patients with resectable non–small cell lung cancer: the neotorch randomized clinical trial
US20250154274A1 (en) Use of anti-pd-1 antibody in combination with anti-cd27 antibody in cancer treatment
Cohen et al. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC)
KR102610764B1 (ko) 암을 치료하기 위한 카보잔티닙 및 아테졸리주맙의 조합
Alden et al. Salvage ipilimumab plus nivolumab after anti-PD-1/PD-L1 therapy in advanced hepatocellular carcinoma
JP2013067645A (ja) 転移性乳癌の治療
JP2022518236A (ja) 進行期固形腫瘍がんに対する治療用rnaおよび抗pd1抗体
JP2019503387A (ja) 抗pd−1抗体および別の抗癌剤の組合せを用いる肺癌の処置法
Tu et al. Case report: a case of sintilimab-induced cystitis/ureteritis and review of sintilimab-related adverse events
Wick et al. Molecularly matched targeted therapies plus radiotherapy in glioblastoma: the phase 1/2a N2M2 umbrella trial
Chang et al. The current management of alveolar soft part sarcomas
Guo et al. Relationship between TIGIT expression on T cells and the prognosis of patients with hepatocellular carcinoma
US20260098087A1 (en) Dosages of emactuzumab
Bozorgmehr et al. Reconsidering palliative radiotherapy in addition to PD-1 blockade for non-small cell lung cancer: results from the FORCE phase II trial (AIO/YMO-TRK-0415)
JP2020509035A (ja) 手術後の肝細胞癌患者を治療するための薬剤の製造における硫酸化オリゴ糖の使用
Zeng et al. Adebrelimab combined with anlotinib plus hepatic arterial infusion chemotherapy or intravenous chemotherapy for first-line treatment of advanced biliary tract cancer: protocol for a randomized open-label clinical study
KR20240162547A (ko) 화학요법과 조합하여 항-pd-l1 항체를 사용하여 담도암을 치료하는 방법
Subudhi A pilot trial to explore the link between immunological changes, efficacy, safety and tolerability of durvalumab (MEDI4736) plus tremelimumab in chemotherapy-naïve men with metastatic castration-resistant prostate cancer (CRPC)
TW202529802A (zh) 胃癌和/或胃食管結合部癌的治療
Khan et al. Failure of the PD-1 blocking agent pembrolizumab to benefit a patient with renal squamous cell cancer
Gouveia et al. Immunotherapy-Associated Autoimmune Hemolytic Anemia: Two Case Reports and a Literature Review
DEVELOPM Drug DeveloPment
EA051386B1 (ru) Соторасиб и антитело к egfr для лечения рака, предусматривающего мутацию kras g12c

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200521

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200521

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20200521

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20200610

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200707

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200818

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20201124

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210511

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210719

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210907

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210910

R150 Certificate of patent or registration of utility model

Ref document number: 6948080

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250